HRTIS — Herantis Pharma Oyj Share News
0.000.00%
Last trade - 00:00Brief: Herantis Pharma Announces Positive Interim Data From Lymfactin Study
Brief: Herantis Pharma H2 Net loss at EUR 136,700
Brief: Herantis Pharma Reports Delay Of Lymfactin Phase 1 Study
Brief: Herantis Pharma says decided on directed share issue of 800,000 new shares at subscription price of Eur 5.85 per share
Brief: Herantis Pharma may issue maximum of 800,000 shares
Brief: Herantis Pharma plans a directed share issue
Brief: Herantis pharma says does not expect essential revenues in 2017
Brief: Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland
Brief: Herantis Pharma H2 loss shrinks to EUR 1.8 million
Brief: Herantis Pharma wins EUR 6.0 million grant for Parkinson study
Brief: Herantis Pharma and Renishaw sign collaboration agreement on Parkinson's study
Brief: Herantis Pharma H1 operating loss narrows to 2.6 million euros
Brief: Herantis Pharma gets orphan designation in USA for CDNF for treatment of ALS
Brief: Herantis Pharma receives orphan designation of CDNF for treatment of ALS
Brief: Herantis Pharma announces decision in arbitration proceedings with Finvector
Brief: Herantis Pharma 2015 operating loss widens to EUR 16.2 million
Brief: Herantis Pharma: directed share issue to Broadview Ventures I
Brief: Herantis Pharma elaborates on its outlook for 2016
Brief: Herantis Pharma: Finnish Medicines Agency authorization of clinical study with Lymfactin